CTI is developing medicines to help treat your cancer while maintaining your quality of life.
Pixantrone is marketed by CTI in the EU as Pixuvri®.
Summary of Product Characteristics and Package InsertLearn about our potential treatments for non-Hodgkin Lymphoma.
See Phase 3 PipelineLearn about our potential treatments for Acute Myeloid Leukemia (AML), Myelodysplasia (MDS).
See Phase 1 PipelineCell Therapeutics to Present at Upcoming Investor Conferences
Cell Therapeutics Reports First Quarter 2013 Financial Results
Cell Therapeutics, Inc. at UBS Global Healthcare Conference
Q1 2013 Cell Therapeutics, Inc. Earnings Conference Call
PIXUVRI is the only medicine approved as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell lymphomas in the E.U.
Download Summary of Product Characteristics and Package Insert
Pixantrone is marketed in the E.U. as PIXUVRI | Learn more
Our late-stage development pipeline addresses a full complement of blood-related cancers.
learn about our oncology pipeline